» Articles » PMID: 33643046

Alnus Hirsuta (Spach) Rupr. Attenuates Airway Inflammation and Mucus Overproduction in a Murine Model of Ovalbumin-Challenged Asthma

Overview
Journal Front Pharmacol
Date 2021 Mar 1
PMID 33643046
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

(Spach) Rupr. (AH), a member of the Betulaceae family, is widely used in Eastern Asia of as a source of medicinal compounds for the treatment of hemorrhage, diarrhea, and alcoholism. In this study, we investigated the protective effects of a methanolic extract of AH branches against airway inflammation and mucus production in tumor necrosis factor (TNF)-α-stimulated NCI-H292 cells and in an ovalbumin (OVA)-challenged allergic asthma mouse model. Female BALB/c mice were injected with OVA (40 μg) and aluminum hydroxide (2 mg) on days 0 and 14 to induce allergic airway inflammation. The mice were then challenged with 1% OVA from days 21-23. Mice were treated with AH (50 and 100 mg/kg/day; 2% DMSO) or dexamethasone (positive control; 3 mg/kg/day) from days 18-23. AH treatment effectively attenuated airway resistance/hyperresponsiveness and reduced levels of T helper type 2 (Th2) cytokines, eotaxins, and number of inflammatory cells in bronchoalveolar lavage fluid, and immunoglobulin E in serums of OVA-challenged mice. In histological analysis, AH treatment significantly inhibited airway inflammation and mucus production in OVA-challenged mice. AH treatment downregulated the phosphorylation of I kappa B-alpha, p65 nuclear factor-kappa B (p65NF-κB), and mitogen-activated protein kinases with suppression of mucin 5AC (MUC5AC) in lung tissue. Moreover, AH treatment decreased the levels of pro-inflammatory cytokines and Th2 cytokines, as well as MUC5AC expression, and inhibited the phosphorylation of p65NF-κB in TNF-α-stimulated NCI-H292 cells. These results indicate that AH might represent a useful therapeutic agent for the treatment of allergic asthma.

Citing Articles

An Updated Comprehensive Review of Plants and Herbal Compounds with Antiasthmatic Effect.

Rajizadeh M, Najafipour H, Bejeshk M Evid Based Complement Alternat Med. 2024; 2024:5373117.

PMID: 39263346 PMC: 11390241. DOI: 10.1155/2024/5373117.


The miR-124-3p regulates the allergic airway inflammation and remodeling in an ovalbumin-asthmatic mouse model by inhibiting S100A4.

Liu M, Liu S, Li F, Li C, Chen S, Gao X Immun Inflamm Dis. 2023; 11(2):e730.

PMID: 36799806 PMC: 9896513. DOI: 10.1002/iid3.730.

References
1.
Park D, Kim H, Jung S, Yook C, Jin C, Lee Y . A new diarylheptanoid glycoside from the stem bark of Alnus hirsuta and protective effects of diarylheptanoid derivatives in human HepG2 cells. Chem Pharm Bull (Tokyo). 2010; 58(2):238-41. DOI: 10.1248/cpb.58.238. View

2.
Alam R, Gorska M . Mitogen-activated protein kinase signalling and ERK1/2 bistability in asthma. Clin Exp Allergy. 2010; 41(2):149-59. PMC: 3115726. DOI: 10.1111/j.1365-2222.2010.03658.x. View

3.
Shin N, Ryu H, Ko J, Park S, Yuk H, Kim H . Artemisia argyi attenuates airway inflammation in ovalbumin-induced asthmatic animals. J Ethnopharmacol. 2017; 209:108-115. DOI: 10.1016/j.jep.2017.07.033. View

4.
Sung Y, Kim S, Yuk H, Yang W, Lee Y, Son E . Siraitia grosvenorii residual extract attenuates ovalbumin-induced lung inflammation by down-regulating IL-4, IL-5, IL-13, IL-17, and MUC5AC expression in mice. Phytomedicine. 2019; 61:152835. DOI: 10.1016/j.phymed.2019.152835. View

5.
Halwani R, Al-Muhsen S, Hamid Q . Airway remodeling in asthma. Curr Opin Pharmacol. 2010; 10(3):236-45. DOI: 10.1016/j.coph.2010.06.004. View